nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—REN—osteoporosis	0.0152	0.198	CbGpPWpGaD
Azilsartan medoxomil—Blood creatinine increased—Ibandronate—osteoporosis	0.0122	0.0133	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Calcitriol—osteoporosis	0.012	0.013	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Pamidronate—osteoporosis	0.00957	0.0104	CcSEcCtD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—ACE—osteoporosis	0.00948	0.124	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Estropipate—osteoporosis	0.00927	0.0101	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Alendronate—osteoporosis	0.00913	0.00991	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Etidronic acid—osteoporosis	0.0091	0.00988	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Raloxifene—osteoporosis	0.00898	0.00975	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Raloxifene—osteoporosis	0.00896	0.00973	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Ibandronate—osteoporosis	0.00889	0.00965	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Ibandronate—osteoporosis	0.00887	0.00963	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Zoledronate—osteoporosis	0.00874	0.00949	CcSEcCtD
Azilsartan medoxomil—Angioedema—Etidronic acid—osteoporosis	0.00865	0.00939	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Estropipate—osteoporosis	0.00854	0.00927	CcSEcCtD
Azilsartan medoxomil—Asthenia—Calcium Acetate—osteoporosis	0.00844	0.00917	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Conjugated Estrogens—osteoporosis	0.00842	0.00914	CcSEcCtD
Azilsartan medoxomil—Pruritus—Calcium Acetate—osteoporosis	0.00833	0.00904	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Raloxifene—osteoporosis	0.00827	0.00898	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Ibandronate—osteoporosis	0.00819	0.00889	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Calcium Acetate—osteoporosis	0.00805	0.00874	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Estropipate—osteoporosis	0.00787	0.00855	CcSEcCtD
Azilsartan medoxomil—Dizziness—Calcium Acetate—osteoporosis	0.00778	0.00845	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Alendronate—osteoporosis	0.00776	0.00842	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Raloxifene—osteoporosis	0.00763	0.00828	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Ibandronate—osteoporosis	0.00755	0.0082	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Ethinyl Estradiol—osteoporosis	0.00749	0.00814	CcSEcCtD
Azilsartan medoxomil—Angioedema—Estropipate—osteoporosis	0.00748	0.00813	CcSEcCtD
Azilsartan medoxomil—Asthenia—Ergocalciferol—osteoporosis	0.00746	0.0081	CcSEcCtD
Azilsartan medoxomil—Angioedema—Alendronate—osteoporosis	0.00737	0.008	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Risedronate—osteoporosis	0.00733	0.00795	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Risedronate—osteoporosis	0.00731	0.00793	CcSEcCtD
Azilsartan medoxomil—Angioedema—Ibandronate—osteoporosis	0.00718	0.00779	CcSEcCtD
Azilsartan medoxomil—Nausea—Calcium Acetate—osteoporosis	0.00699	0.00759	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Pamidronate—osteoporosis	0.00695	0.00754	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.00693	0.00752	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Ethinyl Estradiol—osteoporosis	0.00692	0.00751	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Risedronate—osteoporosis	0.00675	0.00733	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.00671	0.00728	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00664	0.00721	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TUBA1B—osteoporosis	0.00658	0.0858	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Estropipate—osteoporosis	0.00656	0.00712	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Estropipate—osteoporosis	0.00649	0.00705	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Pamidronate—osteoporosis	0.00641	0.00696	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Ethinyl Estradiol—osteoporosis	0.00638	0.00693	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Zoledronate—osteoporosis	0.00636	0.00691	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Raloxifene—osteoporosis	0.00635	0.0069	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Zoledronate—osteoporosis	0.00634	0.00689	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Raloxifene—osteoporosis	0.00629	0.00683	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Ibandronate—osteoporosis	0.00629	0.00683	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Ibandronate—osteoporosis	0.00623	0.00676	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Risedronate—osteoporosis	0.00622	0.00676	CcSEcCtD
Azilsartan medoxomil—Nausea—Ergocalciferol—osteoporosis	0.00618	0.00671	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Conjugated Estrogens—osteoporosis	0.00612	0.00665	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Calcitriol—osteoporosis	0.0061	0.00662	CcSEcCtD
Azilsartan medoxomil—Angioedema—Ethinyl Estradiol—osteoporosis	0.00607	0.00659	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Pamidronate—osteoporosis	0.00592	0.00642	CcSEcCtD
Azilsartan medoxomil—Angioedema—Risedronate—osteoporosis	0.00591	0.00642	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Zoledronate—osteoporosis	0.00586	0.00636	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Estropipate—osteoporosis	0.00577	0.00627	CcSEcCtD
Azilsartan medoxomil—Fatigue—Estropipate—osteoporosis	0.00576	0.00626	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Conjugated Estrogens—osteoporosis	0.00564	0.00613	CcSEcCtD
Azilsartan medoxomil—Angioedema—Pamidronate—osteoporosis	0.00562	0.00611	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.00561	0.0061	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00559	0.00607	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00553	0.00601	CcSEcCtD
Azilsartan medoxomil—Fatigue—Ibandronate—osteoporosis	0.00553	0.006	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.00547	0.00594	CcSEcCtD
Azilsartan medoxomil—Pruritus—Etidronic acid—osteoporosis	0.00547	0.00594	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Zoledronate—osteoporosis	0.0054	0.00587	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00531	0.00577	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Etidronic acid—osteoporosis	0.00529	0.00574	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00526	0.00572	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Conjugated Estrogens—osteoporosis	0.0052	0.00565	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Risedronate—osteoporosis	0.00518	0.00563	CcSEcCtD
Azilsartan medoxomil—Angioedema—Zoledronate—osteoporosis	0.00514	0.00558	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Risedronate—osteoporosis	0.00513	0.00557	CcSEcCtD
Azilsartan medoxomil—Angioedema—Conjugated Estrogens—osteoporosis	0.00495	0.00537	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Pamidronate—osteoporosis	0.00493	0.00535	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Estradiol—osteoporosis	0.0049	0.00532	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Estradiol—osteoporosis	0.00489	0.00531	CcSEcCtD
Azilsartan medoxomil—Rash—Etidronic acid—osteoporosis	0.00487	0.00529	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Etidronic acid—osteoporosis	0.00487	0.00529	CcSEcCtD
Azilsartan medoxomil—Asthenia—Estropipate—osteoporosis	0.0048	0.00521	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00475	0.00516	CcSEcCtD
Azilsartan medoxomil—Pruritus—Estropipate—osteoporosis	0.00473	0.00514	CcSEcCtD
Azilsartan medoxomil—Asthenia—Alendronate—osteoporosis	0.00472	0.00513	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00468	0.00508	CcSEcCtD
Azilsartan medoxomil—Fatigue—Ethinyl Estradiol—osteoporosis	0.00467	0.00507	CcSEcCtD
Azilsartan medoxomil—Pruritus—Alendronate—osteoporosis	0.00466	0.00506	CcSEcCtD
Azilsartan medoxomil—Asthenia—Ibandronate—osteoporosis	0.0046	0.00499	CcSEcCtD
Azilsartan medoxomil—Nausea—Etidronic acid—osteoporosis	0.00459	0.00498	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00458	0.00497	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Estropipate—osteoporosis	0.00457	0.00497	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Risedronate—osteoporosis	0.00456	0.00495	CcSEcCtD
Azilsartan medoxomil—Fatigue—Risedronate—osteoporosis	0.00455	0.00495	CcSEcCtD
Azilsartan medoxomil—Pruritus—Ibandronate—osteoporosis	0.00454	0.00492	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Estradiol—osteoporosis	0.00451	0.0049	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Alendronate—osteoporosis	0.0045	0.00489	CcSEcCtD
Azilsartan medoxomil—Asthenia—Calcitriol—osteoporosis	0.0045	0.00489	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Zoledronate—osteoporosis	0.0045	0.00488	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Zoledronate—osteoporosis	0.00446	0.00484	CcSEcCtD
Azilsartan medoxomil—Pruritus—Calcitriol—osteoporosis	0.00444	0.00482	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Raloxifene—osteoporosis	0.00443	0.00481	CcSEcCtD
Azilsartan medoxomil—Dizziness—Estropipate—osteoporosis	0.00442	0.0048	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Ibandronate—osteoporosis	0.00439	0.00476	CcSEcCtD
Azilsartan medoxomil—Dizziness—Alendronate—osteoporosis	0.00435	0.00473	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00434	0.00471	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.00433	0.0047	CcSEcCtD
Azilsartan medoxomil—Fatigue—Pamidronate—osteoporosis	0.00433	0.0047	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Calcitriol—osteoporosis	0.00429	0.00466	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Conjugated Estrogens—osteoporosis	0.00429	0.00466	CcSEcCtD
Azilsartan medoxomil—Dizziness—Raloxifene—osteoporosis	0.00428	0.00465	CcSEcCtD
Azilsartan medoxomil—Dizziness—Ibandronate—osteoporosis	0.00424	0.0046	CcSEcCtD
Azilsartan medoxomil—Rash—Estropipate—osteoporosis	0.00421	0.00458	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Estropipate—osteoporosis	0.00421	0.00457	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Estradiol—osteoporosis	0.00416	0.00452	CcSEcCtD
Azilsartan medoxomil—Rash—Alendronate—osteoporosis	0.00415	0.00451	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Alendronate—osteoporosis	0.00415	0.0045	CcSEcCtD
Azilsartan medoxomil—Rash—Raloxifene—osteoporosis	0.00408	0.00443	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Raloxifene—osteoporosis	0.00408	0.00443	CcSEcCtD
Azilsartan medoxomil—Rash—Ibandronate—osteoporosis	0.00404	0.00439	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Ibandronate—osteoporosis	0.00404	0.00438	CcSEcCtD
Azilsartan medoxomil—Nausea—Estropipate—osteoporosis	0.00397	0.00431	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00396	0.0043	CcSEcCtD
Azilsartan medoxomil—Angioedema—Estradiol—osteoporosis	0.00396	0.0043	CcSEcCtD
Azilsartan medoxomil—Rash—Calcitriol—osteoporosis	0.00396	0.0043	CcSEcCtD
Azilsartan medoxomil—Fatigue—Zoledronate—osteoporosis	0.00395	0.00429	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Calcitriol—osteoporosis	0.00395	0.00429	CcSEcCtD
Azilsartan medoxomil—Nausea—Alendronate—osteoporosis	0.00391	0.00425	CcSEcCtD
Azilsartan medoxomil—Asthenia—Ethinyl Estradiol—osteoporosis	0.00389	0.00422	CcSEcCtD
Azilsartan medoxomil—Nausea—Raloxifene—osteoporosis	0.00385	0.00418	CcSEcCtD
Azilsartan medoxomil—Pruritus—Ethinyl Estradiol—osteoporosis	0.00383	0.00416	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00381	0.00414	CcSEcCtD
Azilsartan medoxomil—Fatigue—Conjugated Estrogens—osteoporosis	0.00381	0.00414	CcSEcCtD
Azilsartan medoxomil—Nausea—Ibandronate—osteoporosis	0.00381	0.00413	CcSEcCtD
Azilsartan medoxomil—Asthenia—Risedronate—osteoporosis	0.00379	0.00412	CcSEcCtD
Azilsartan medoxomil—Pruritus—Risedronate—osteoporosis	0.00374	0.00406	CcSEcCtD
Azilsartan medoxomil—Nausea—Calcitriol—osteoporosis	0.00373	0.00405	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.00371	0.00403	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00366	0.00398	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Risedronate—osteoporosis	0.00361	0.00393	CcSEcCtD
Azilsartan medoxomil—Asthenia—Pamidronate—osteoporosis	0.0036	0.00391	CcSEcCtD
Azilsartan medoxomil—Dizziness—Ethinyl Estradiol—osteoporosis	0.00358	0.00389	CcSEcCtD
Azilsartan medoxomil—Pruritus—Pamidronate—osteoporosis	0.00355	0.00386	CcSEcCtD
Azilsartan medoxomil—Dizziness—Risedronate—osteoporosis	0.00349	0.00379	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Estradiol—osteoporosis	0.00347	0.00376	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Pamidronate—osteoporosis	0.00344	0.00373	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Estradiol—osteoporosis	0.00343	0.00373	CcSEcCtD
Azilsartan medoxomil—Rash—Ethinyl Estradiol—osteoporosis	0.00342	0.00371	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00341	0.00371	CcSEcCtD
Azilsartan medoxomil—Rash—Risedronate—osteoporosis	0.00333	0.00362	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Risedronate—osteoporosis	0.00333	0.00361	CcSEcCtD
Azilsartan medoxomil—Dizziness—Pamidronate—osteoporosis	0.00332	0.00361	CcSEcCtD
Azilsartan medoxomil—Asthenia—Zoledronate—osteoporosis	0.00329	0.00357	CcSEcCtD
Azilsartan medoxomil—Pruritus—Zoledronate—osteoporosis	0.00325	0.00352	CcSEcCtD
Azilsartan medoxomil—Nausea—Ethinyl Estradiol—osteoporosis	0.00322	0.00349	CcSEcCtD
Azilsartan medoxomil—Asthenia—Conjugated Estrogens—osteoporosis	0.00317	0.00344	CcSEcCtD
Azilsartan medoxomil—Rash—Pamidronate—osteoporosis	0.00317	0.00344	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Pamidronate—osteoporosis	0.00316	0.00344	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Zoledronate—osteoporosis	0.00314	0.00341	CcSEcCtD
Azilsartan medoxomil—Nausea—Risedronate—osteoporosis	0.00314	0.00341	CcSEcCtD
Azilsartan medoxomil—Pruritus—Conjugated Estrogens—osteoporosis	0.00313	0.00339	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Estradiol—osteoporosis	0.00305	0.00331	CcSEcCtD
Azilsartan medoxomil—Fatigue—Estradiol—osteoporosis	0.00305	0.00331	CcSEcCtD
Azilsartan medoxomil—Dizziness—Zoledronate—osteoporosis	0.00303	0.00329	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Conjugated Estrogens—osteoporosis	0.00302	0.00328	CcSEcCtD
Azilsartan medoxomil—Nausea—Pamidronate—osteoporosis	0.00298	0.00324	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—MGLL—osteoporosis	0.00294	0.0384	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Conjugated Estrogens—osteoporosis	0.00292	0.00317	CcSEcCtD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—TGFB1—osteoporosis	0.00292	0.038	CbGpPWpGaD
Azilsartan medoxomil—Rash—Zoledronate—osteoporosis	0.00289	0.00314	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Zoledronate—osteoporosis	0.00289	0.00314	CcSEcCtD
Azilsartan medoxomil—Rash—Conjugated Estrogens—osteoporosis	0.00279	0.00302	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Conjugated Estrogens—osteoporosis	0.00278	0.00302	CcSEcCtD
Azilsartan medoxomil—Nausea—Zoledronate—osteoporosis	0.00272	0.00296	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.00263	0.0343	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Conjugated Estrogens—osteoporosis	0.00262	0.00285	CcSEcCtD
Azilsartan medoxomil—Asthenia—Estradiol—osteoporosis	0.00254	0.00275	CcSEcCtD
Azilsartan medoxomil—Pruritus—Estradiol—osteoporosis	0.0025	0.00272	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Estradiol—osteoporosis	0.00242	0.00263	CcSEcCtD
Azilsartan medoxomil—Losartan—ACE—osteoporosis	0.00237	1	CrCbGaD
Azilsartan medoxomil—Dizziness—Estradiol—osteoporosis	0.00234	0.00254	CcSEcCtD
Azilsartan medoxomil—Rash—Estradiol—osteoporosis	0.00223	0.00242	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Estradiol—osteoporosis	0.00223	0.00242	CcSEcCtD
Azilsartan medoxomil—Nausea—Estradiol—osteoporosis	0.0021	0.00228	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTH1R—osteoporosis	0.00187	0.0244	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CALCR—osteoporosis	0.00187	0.0244	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.00147	0.0191	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.00126	0.0164	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—osteoporosis	0.00115	0.015	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL1B—osteoporosis	0.0011	0.0143	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTH1R—osteoporosis	0.00106	0.0138	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CALCR—osteoporosis	0.00106	0.0138	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTH—osteoporosis	0.000981	0.0128	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTH1R—osteoporosis	0.000959	0.0125	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CALCR—osteoporosis	0.000959	0.0125	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CNR2—osteoporosis	0.000956	0.0125	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—WNT1—osteoporosis	0.000899	0.0117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TGFB1—osteoporosis	0.000853	0.0111	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—MGLL—osteoporosis	0.000839	0.0109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTHLH—osteoporosis	0.000813	0.0106	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—osteoporosis	0.000797	0.0104	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MGLL—osteoporosis	0.000762	0.00993	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—POMC—osteoporosis	0.000733	0.00956	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CALCA—osteoporosis	0.000716	0.00933	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000648	0.00845	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SOST—osteoporosis	0.000626	0.00816	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CALCR—osteoporosis	0.000566	0.00738	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTH1R—osteoporosis	0.000566	0.00738	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTH—osteoporosis	0.000555	0.00723	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CNR2—osteoporosis	0.00054	0.00705	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTH—osteoporosis	0.000504	0.00657	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000492	0.00641	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CNR2—osteoporosis	0.000491	0.0064	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—WNT1—osteoporosis	0.000461	0.00602	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTHLH—osteoporosis	0.00046	0.00599	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MGLL—osteoporosis	0.00045	0.00587	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LRP5—osteoporosis	0.000439	0.00573	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LRP6—osteoporosis	0.00042	0.00548	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTHLH—osteoporosis	0.000417	0.00544	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CALCA—osteoporosis	0.000405	0.00527	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—POMC—osteoporosis	0.000375	0.00488	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CALCA—osteoporosis	0.000367	0.00479	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TLN1—osteoporosis	0.000355	0.00462	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—P4HB—osteoporosis	0.000306	0.00399	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTH—osteoporosis	0.000298	0.00388	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RAP1A—osteoporosis	0.000292	0.00381	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CNR2—osteoporosis	0.00029	0.00378	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000289	0.00376	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADCY5—osteoporosis	0.000288	0.00375	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NFATC1—osteoporosis	0.000285	0.00372	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—DKK1—osteoporosis	0.000283	0.00369	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—WNT1—osteoporosis	0.000273	0.00355	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGA—osteoporosis	0.000265	0.00346	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADCY5—osteoporosis	0.000261	0.00341	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTHLH—osteoporosis	0.000247	0.00321	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BMP2—osteoporosis	0.000247	0.00321	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGB—osteoporosis	0.000241	0.00315	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PSMA2—osteoporosis	0.000233	0.00304	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PSMA5—osteoporosis	0.000233	0.00304	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CALCA—osteoporosis	0.000217	0.00283	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—POMC—osteoporosis	0.000212	0.00276	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KL—osteoporosis	0.000197	0.00257	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—POMC—osteoporosis	0.000192	0.00251	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6R—osteoporosis	0.000188	0.00244	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADCY5—osteoporosis	0.000154	0.00201	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SPP1—osteoporosis	0.000149	0.00195	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IRS2—osteoporosis	0.000135	0.00176	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEP—osteoporosis	0.000132	0.00172	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ESR1—osteoporosis	0.000126	0.00165	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IRS1—osteoporosis	0.000118	0.00154	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—POMC—osteoporosis	0.000114	0.00148	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6R—osteoporosis	0.000111	0.00144	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1—osteoporosis	0.000109	0.00142	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—osteoporosis	8.35e-05	0.00109	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYC—osteoporosis	6.56e-05	0.000856	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFB1—osteoporosis	6.55e-05	0.000854	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—osteoporosis	4.93e-05	0.000643	CbGpPWpGaD
